Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05538767
Other study ID # EMODEPSIDE_PEMBA
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 16, 2022
Est. completion date April 11, 2023

Study information

Verified date June 2023
Source Swiss Tropical & Public Health Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the efficacy and safety of emodepside to that of albendazole (Zentel®) in participants aged 12-60, inclusive, infected with hookworm.


Recruitment information / eligibility

Status Completed
Enrollment 320
Est. completion date April 11, 2023
Est. primary completion date April 11, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 60 Years
Eligibility Inclusion Criteria: - Male or female adults aged between 12 and 60 years; - Written and signed informed consent; - Was examined by a study physician before treatment; - Provided two stool samples at baseline; - Hookworm EPG > 48 and at least two Kato-Katz thick smears slides with more than one hookworm eggs. Exclusion Criteria: - Pregnant or lactating and/or planning to become pregnant within three months after drug treatment; - Type 1 and/or 2 diabetes; - Psychiatric disorders; - History of ophthalmological conditions; - Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment; - Suffers from severe anaemia (Hb < 80 g/l); - Received anthelminthic treatment within past four weeks; - Attending other clinical trials during the study; - Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin; - Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir. - Participated in stage I trials of this protocol

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Emodepside
Treatment with Emodepside 30 mg
Albendazole 400mg
Treatment with Albendazole 400 mg

Locations

Country Name City State
Tanzania Public Health Laboratory Ivo de Carneri Chake Chake Pemba

Sponsors (2)

Lead Sponsor Collaborator
Jennifer Keiser Public Health Laboratory Ivo de Carneri

Country where clinical trial is conducted

Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cure rate (CR) of emodepside against hookworm CR will be calculated as the percentage of hookworm egg-positive participants at baseline who become egg-negative after treatment. In the week between 14 and 21 days post-treatment
Secondary Geometric Mean Egg Reduction Rate (ERR) of the emodepside against hookworm. Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100). In the week between 14 and 21 days post-treatment
Secondary CR of emodepside against Trichuris trichiura and Ascaris lumbricoides CR will be calculated as the percentage of Trichuris trichiura and Ascaris lumbricoides egg-positive participants at baseline who become egg-negative after treatment. In the week between 14 and 21 days post-treatment
Secondary ERR of the emodepside against Trichuris trichiura and Ascaris lumbricoides. EPG will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The ERR is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100). In the week between 14 and 21 days post-treatment
Secondary Infection status and intensity assessed for at baseline and 14-21 days post-treatment by FECPAK-G2. At baseline and 14-21 days post-treatment
See also
  Status Clinical Trial Phase
Withdrawn NCT03261596 - Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana Phase 4
Completed NCT03527745 - Albendazole Dose Finding and Pharmacokinetics in Children and Adults Phase 2
Active, not recruiting NCT06188715 - Efficacy and Safety of MOX/ALB Co-administration in SAC Phase 3
Active, not recruiting NCT04227834 - Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education N/A
Completed NCT04700423 - Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration Phase 2/Phase 3
Completed NCT03172975 - Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection Phase 2
Recruiting NCT06184399 - Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC Phase 2
Completed NCT04726969 - Efficacy and Safety of MOX/ALB Co-administration Phase 3
Completed NCT03995680 - Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm Phase 2
Completed NCT05017194 - Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm Phase 2
Completed NCT01163877 - Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma N/A